Align Technology Stock
€146.95
Your prediction
Align Technology Stock
Align Technology (NASDAQ: ALGN) is a leading global medical device company specializing in the design, manufacture, and marketing of comprehensive orthodontic systems. Their flagship product, the Invisalign system, revolutionizes traditional orthodontic treatment by offering an innovative clear-aligner solution that guides teeth into proper alignment without the use of conventional metal braces or wires. Founded in 1997, Align Technology has expanded its product portfolio to include iTero intraoral scanning and CAD/CAM technologies, alongside spearheading research and development in dental solutions. By embracing digital technology and focusing on patient convenience and comfort, Align has quickly established itself as a significant player within the growing dental and orthodontic industry, consistently leading the charge for new, non-invasive solutions to dental malocclusion.
Pros and Cons of Align Technology in the next few years
Pros
Cons
Performance of Align Technology vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Align Technology | 0.070% | -2.393% | -10.757% | 25.032% | 9.263% | -55.283% | -75.102% |
| Dexcom Inc. | 0.550% | 11.420% | 13.880% | 10.162% | 25.960% | -33.967% | -34.274% |
| Baxter International | 0.680% | 0.991% | 18.834% | 21.400% | 43.874% | -41.327% | -63.168% |
| Idexx Laboratories Inc. | -0.940% | 5.674% | 3.726% | -4.369% | -12.385% | 11.785% | -12.023% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Align Technology (ALGN) - FY2025 Annual Report
Align Technology appears to have entered a period of near-stagnation on the top line while facing gradual margin compression. Revenue reached roughly $4.03 billion, essentially flat against the prior year, while net income slipped modestly to $410 million. The company continues to operate without debt and holds a substantial cash cushion, suggesting a financially conservative posture even as growth momentum appears to have faded considerably from the exceptional levels seen in 2021.
What stands out most is the multi-year erosion in profitability metrics. Gross margin, which sat above 74% in 2021, has drifted down to roughly 67%, and operating margin appears to have compressed for a fourth consecutive year to around 13.5%. The trajectory seems particularly pronounced in the core Clear Aligner segment, where gross profit declined despite modestly higher revenue, indicating rising unit costs. In contrast, the Systems and Services segment appears to be a relative bright spot, with operating income continuing to climb. The geographic mix is also shifting notably: U.S. revenue has stagnated and Switzerland has declined meaningfully, while "Other International" has become the largest contributor, which could suggest a growing reliance on emerging markets for volume.
Comments
